Olequat Limited

OleQuat Limited is a biotechnology company developing a new class of olefinic quaternary ammonium compounds (oQACs). These patent-protected, next-generation compounds are engineered to provide broad-spectrum, anti-biofilm antimicrobial activity while offering reduced toxicity and lower environmental persistence compared to traditional QACs. The technology utilizes a green chemistry method to create these molecules, which are currently being evaluated for their stability, resistance development, and performance in various formulations. Scientific development is led by co-founders Dr. Alan Cameron and Dr. Kristi Biswas, who are supported by CEO Craig Squire in commercial strategy and partnership development.

The company is focused on addressing the global challenge of antimicrobial resistance by providing safer and more versatile antimicrobial solutions. Their research has potential applications ranging from low-dose preservatives and high-performance surface sanitisers to future topical therapeutic uses on human skin and mucosal surfaces. Currently in the preclinical stage, the team is conducting testing to build the evidentiary data required for regulatory review and eventual commercial or clinical adoption. Through strategic engagement with research innovation programs, OleQuat is actively validating market requirements to balance regulatory-intensive medical needs with more immediate commercial opportunities in consumer and industrial sectors.